Vir Biotechnology outlines accelerated hepatitis delta milestones and cash runway into mid-2027 as ECLIPSE 1 completes enrollment early (NASDAQ:VIR) - Reportify

Vir Biotechnology outlines accelerated hepatitis delta milestones and cash runway into mid-2027 as ECLIPSE 1 completes enrollment early (NASDAQ:VIR)

Vir(US:VIR) Seeking Alpha·2025-11-06 02:42

技术访问问题 - 为确保未来正常访问需在浏览器中启用Javascript和cookies [1] - 启用广告拦截器可能导致访问被阻止需禁用广告拦截器并刷新页面 [1]